Home


Login | Forgot password?
May 18, 2012
A new path to hope

Brainsgate is a medical device company committed to developing a novel treatment modality, electrical SPG stimulation. This platform technology has been shown to increase blood flow to the brain and as a result has broad potential for treating central nervous system disorders. BrainsGate is currently focusing on:

1. Improve the outcome of patients suffering from ischemic stroke, in a 24 hour window after onset of symptoms.

2. Long-term SPG stimulation for the treatment of vascular dementia patients.


Focus: Stroke
The leading cause of adult long-term disability and the third leading cause of death read more
Focus: the spheno-palatine ganglion
Two small nervous centers located above the roof of the mouth near the sinuses read more
May 26, 2011
ImpACT-24b Trial Launch
BrainsGate launches the ImpACT-24b at the European Stroke Conference 2011 in Hamburg > full story
November 17, 2009
Investigational Neurostimulation Device Aims to Reduce Stroke Damage
Stroke researchers at the Methodist Neurological Institute in Houston are the only ones in Texas to offer a novel device that might extend the acute stroke treatment window from three hours to 24 (PhysOrg.com) > full story